TrianglePUBLICATIONS · 20564086
Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Cancer
- Publication date
- 2010 Aug 15
- First author
- Saglio G
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Saglio G
- type
- Author
- name
- Hochhaus A
- type
- Author
- name
- Goh YT
- type
- Author
- name
- Masszi T
- type
- Author
- name
- Pasquini R
- type
- Author
- name
- Maloisel F
- type
- Author
- name
- Erben P
- type
- Author
- name
- Cortes J
- type
- Author
- name
- Paquette R
- type
- Author
- name
- Bradley-Garelik MB
- type
- Author
- name
- Zhu C
- type
- Author
- name
- Dombret H
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Saglio G
- type
- Author
- name
- Hochhaus A
- type
- Author
- name
- Goh YT
- type
- Author
- name
- Masszi T
- type
- Author
- name
- Pasquini R
- type
- Author
- name
- Maloisel F
- type
- Author
- name
- Erben P
- type
- Author
- name
- Cortes J
- type
- Author
- name
- Paquette R
- type
- Author
- name
- Bradley-Garelik MB
- type
- Author
- name
- Zhu C
- type
- Author
- name
- Dombret H
- type
- Author
- bibliography ids
- nci-bib-ad5c16bf1b8be20d2dba7d56
- book metadata
- content sha256
- 9a2796fd7acf6c502e5a86f5cf2fc67330117d8a12f682b74c5b4bba3453efbc
- document type
- citation
- dois
- 10.1002/cncr.25123
- electronic publication date
- display
- Source null
- precision
- missing
- year
- Source null
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:20564086
- immutable id
- pubmed:20564086@9a2796fd7acf6c502e5a86f5cf2fc67330117d8a12f682b74c5b4bba3453efbc
- journal
- abbreviation
- Cancer
- issn electronic
- 1097-0142
- issn print
- 0008-543X
- issue
- 16
- name
- Cancer
- nlm unique id
- 0374236
- pages
- 3852-61
- volume
- 116
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 20564086
- provenance
- batch id
- bce21fa556c206e375c2
- provider
- NCBI PubMed ESummary
- record sha256
- 8421dc6eb6b7065b44abe329c7dc04c65ee3c3d1b6bed630f9204a29953e2d6b
- response sha256
- 280642fcc56e65c443f5ee9e69c6371de9e91c70665c7390bba25595a34da323
- retrieved at
- 2026-09-09T23:46:33.526275+00:00
- publication date
- display
- 2010 Aug 15
- precision
- day
- year
- 2010
- publication types
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.
Preserved source evidence · Not medical advice